Should You Buy Bionano Genomics, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Bionano Genomics, Inc. (BNGO) occupies a solid middle-ground position with a Quality of Company score of 5.8/10. At the current market price of $1.56, the investment case depends heavily on whether our 13 independent valuation models indicate a discount to fair value.
The short answer: 2 of 3 CirclFi valuation models project upside for Bionano Genomics, Inc. (BNGO) at $1.56 — the model consensus leans bullish, with a Quality Score of 5.8/10 and Value-Trap risk of 42/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Bionano Genomics, Inc. (BNGO) in 2026?
What Is the Bull Case vs the Bear Case for Bionano Genomics, Inc. (BNGO)?
| Bull case — $5.95 target (+281.5%) | Bear case — $0.53 target (-66.3%) |
|---|---|
| According to the CirclFi Deep Alpha Valuation Engine, 2 of 3 models identify upside from $1.56 to a median fair value of $3.61, indicating the market hasn't fully priced in Bionano Genomics, Inc.'s earnings power. | According to the CirclFi Value Trap algorithm, the stock shows moderate caution signals, meaning investors should verify that apparent undervaluation isn't masking declining business quality. |
| According to the CirclFi Deep Alpha Valuation Engine, the Dynamic NAV model targets a fair value of $5.95 (+281.5%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | According to the CirclFi Deep Alpha Valuation Engine, the ML Residual Income model sees the stock as overvalued with a fair value of $0.53 (-66.3%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +347.8% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology. |
How Does BNGO Compare to Its Medical Instruments & Supplies Peers?
Valuation data pages: KMTS · HBIO · STXS · CUPR · XRAY · LUCY · NNNN · RGEN · OSUR · ISRG · RMD
Which Other Stocks Score Like BNGO on Quality?
Closest companies to BNGO’s Quality of Company score of 5.8/10, across all industries.
- SHAZ — SharonAI Holdings Inc. (QOC 5.8) · analysis
- OZVN — OZ Vision Inc. (QOC 5.8) · analysis
- ABSI — Absci Corporation (QOC 5.8) · analysis
- CSWC — Capital Southwest Corporation (QOC 5.8) · analysis
- ONL — Orion Properties Inc. (QOC 5.8) · analysis
- JBDI — JBDI Holdings Limited (QOC 5.8) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Medical Instruments & Supplies Screens Does BNGO Appear In?
So Is Bionano Genomics, Inc. (BNGO) Worth Buying in 2026?
Bionano Genomics, Inc. leans positive in our analysis — 2/3 models bullish, median fair value of $3.61 vs. $1.56, QOC 5.8/10. The case is constructive but not overwhelming, and the 1 dissenting model shouldn't be dismissed. Position sizing should reflect this moderate conviction level.
These are quantitative model outputs, not investment recommendations. Bionano Genomics, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About BNGO Stock?
Should I buy BNGO stock right now?
Based on CirclFi's multi-model analysis, 2 of 3 models see upside for BNGO at $1.56. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 5.8/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Bionano Genomics, Inc.?
Key risks include: an elevated Value Trap score of 42/100, suggesting apparent undervaluation may mask deteriorating fundamentals; limited model coverage (3/13 active), reducing analytical confidence; wide model disagreement (1032% spread), signaling high uncertainty; general market and sector-specific risks affecting Medical Instruments & Supplies companies. Always diversify and consult a financial advisor.
How does BNGO compare to its competitors?
Among Medical Instruments & Supplies peers, BNGO holds a Quality Score of 5.8/10. Comparable companies include KMTS (QOC 5.8), HBIO (QOC 5.8), STXS (QOC 6.1). The relative ranking helps investors identify whether BNGO offers better fundamental quality than alternatives in the same sector.
Is BNGO a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. BNGO's Quality Score of 5.8/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.
What price should I buy BNGO at?
CirclFi does not provide target buy prices or price alerts. However, our 3 active models produce fair value estimates ranging from $0.53 to $5.95. At $1.56, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for BNGO.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad